Has Ravindra Bollu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,813 in general payments to Ravindra Bollu, MD across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ravindra Bollu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ravindra Bollu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ravindra Bollu, MD

Nephrology · Allentown, PANPI 1194716845

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,625, more than ten times the $19 reported in 2019.

$1,813in general payments, 2019–2025

Across 69 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$249
Boehringer Ingelheim$209
Novartis$154
Veloxis Pharmaceuticals, Inc.$154
Amgen$137
Bayer$128
plus $782 from 15 others

What the payments were for

Food & beverage$1,71695%
Education$975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	9	$249
Boehringer Ingelheim	6	$209
Novartis	5	$154
Veloxis Pharmaceuticals, Inc.	3	$154
Amgen	6	$137
Bayer	4	$128
Lilly USA, LLC	4	$92
Vifor Pharma, Inc.	5	$91
AstraZeneca(2 entities)	4	$85
GSK	3	$72
Mallinckrodt Hospital Products Inc.	1	$59
OPKO Pharmaceuticals, LLC	3	$59
Ardelyx, Inc.	3	$58
Otsuka America Pharmaceutical, Inc.	3	$52
Akebia Therapeutics Inc	2	$49
Calliditas Therapeutics US Inc.	1	$38
Cormedix Inc.	2	$37
Travere Therapeutics, Inc.	2	$27
Apellis Pharmaceuticals, Inc.	1	$24
Shield Therapeutics Inc	1	$19
Scpharmaceuticals Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Ozempic$108

How this compares

$1,813 in reported general payments places this provider in the 70th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$165,928

Medicare patients

447

Services billed

1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	14	$16,149
Valganciclovir Hcl	50	$8,845
Tacrolimus	65	$7,543
Envarsus XrTacrolimus	20	$7,185
Mycophenolate Mofetil	57	$6,939
Mycophenolic AcidMycophenolate Sodium	37	$6,853
Cyclosporine	12	$4,833
Cinacalcet Hcl	38	$3,821
Losartan Potassium	330	$3,697
Leflunomide	58	$2,611
Labetalol Hcl	75	$2,505
Prednisone	256	$2,073
Tamsulosin Hcl	138	$1,646
Nifedipine ErNifedipine	57	$1,532
Metoprolol Succinate	66	$1,506

Paid to pharmacies, not to this prescriber.

Other nephrology in Allentown

Nelson KopytAllentown$949K
Shawn HazlettAllentown$39K
Christopher GislerPittsburgh$757K
Rakesh GulatiPhiladelphia$657K
Raymond TownsendPhiladelphia$357K
Prince AnandDanville$331K
Ellie KelepourisPhiladelphia$287K
Jonathan DiamondHarrisburg$249K
Abdallahsassine GearaPhiladelphia$225K
Khaled NasharPittsburgh$198K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →